LP
SABSW icon

LMR Partners’s SAB Biotherapeutics Warrant SABSW Stock Holding History

LMR Partners’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-539,588
Closed -$19.4K – 1548
2024
Q3 		$19.4K Buy
+539,588
New +$20.2K ﹤0.01% 1123

Other funds holding SABSW

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

LMR Partners's SABSW Position: Q2 2026 in Review

LMR Partners held its SAB Biotherapeutics Warrant (SABSW) position steady in Q2 2026 at 539,588 shares worth $6.91K. The position accounts for ﹤0.01% of the portfolio, ranked #1451.

LMR Partners first reported a position in SABSW in Q4 2021 and has held it in 17 quarters since. The position peaked at $1.27M in Q1 2022. 8 funds tracked by Wall St. Rank hold SABSW as of Q2 2026.

  • LMR Partners held 539,588 shares of SAB Biotherapeutics Warrant worth $6.91K as of Q2 2026.
  • LMR Partners left its SAB Biotherapeutics Warrant share count unchanged in Q2 2026.
  • SAB Biotherapeutics Warrant made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1451 holding.
  • LMR Partners first reported a position in SAB Biotherapeutics Warrant in Q4 2021 and has held it in 17 quarters since.
  • LMR Partners's SAB Biotherapeutics Warrant position peaked at $1.27M in Q1 2022.
  • 8 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.